sorafenib has been researched along with plx 4720 in 13 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (plx 4720) | Trials (plx 4720) | Recent Studies (post-2010) (plx 4720) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 163 | 1 | 151 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (7.69) | 29.6817 |
2010's | 10 (76.92) | 24.3611 |
2020's | 2 (15.38) | 2.80 |
Authors | Studies |
---|---|
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Kim, J; Wang, X | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Agianian, B; Gavathiotis, E | 1 |
Abdel-Maksoud, MS; Ali, EMH; Ammar, UM; Mersal, KI; Oh, CH; Yoo, KH | 1 |
Amaravadi, R; Fecher, LA; Schuchter, LM | 1 |
Fliegel, L; Karki, P; Li, X; Schrama, D | 1 |
Bollag, G | 1 |
Chan, JL; Chen, S; Goydos, JS; Lee, HJ; Namkoong, J; Rosenberg, S; Shin, SS; Wall, BA; Wangari-Talbot, J | 1 |
Braun, S; Brummer, T; Capper, D; Eisenhardt, AE; Fiala, GJ; Halbach, S; Heilmann, K; Herr, R; Röring, M; Saunders, DN; Schamel, WW; von Deimling, A | 1 |
Ahn, SK; Eum, KH; Kang, H; Lee, M | 1 |
Bühler, A; Döhner, H; Jebaraj, BM; Kienle, D; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
Brors, B; Haibe-Kains, B; Kurilov, R | 1 |
1 review(s) available for sorafenib and plx 4720
Article | Year |
---|---|
Current Insights of BRAF Inhibitors in Cancer.
Topics: Animals; Drug Discovery; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf | 2018 |
12 other study(ies) available for sorafenib and plx 4720
Article | Year |
---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Conformation-specific effects of Raf kinase inhibitors.
Topics: Dimerization; Models, Molecular; Protein Conformation; Protein Kinase Inhibitors; raf Kinases | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Pyrroles; Structure-Activity Relationship | 2020 |
Effectively targeting BRAF in melanoma: a formidable challenge.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides; Treatment Outcome | 2008 |
B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger.
Topics: Amino Acid Substitution; Animals; Benzenesulfonates; Cation Transport Proteins; Cell Movement; Cell Size; Extracellular Signal-Regulated MAP Kinases; HEK293 Cells; HeLa Cells; Humans; Hydrogen-Ion Concentration; Indoles; Melanoma; Mutation, Missense; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Isoforms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins B-raf; Pyridines; Rabbits; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfonamides | 2011 |
Setting up a kinase discovery and development project.
Topics: Adenosine Triphosphate; Animals; Crystallography, X-Ray; Drug Discovery; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Enzyme Activation; Enzyme Assays; Humans; Indoles; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Solubility; Sorafenib; Structure-Activity Relationship; Sulfonamides | 2012 |
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glutamic Acid; Indoles; Melanoma; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.
Topics: Benzenesulfonates; Caco-2 Cells; HCT116 Cells; HT29 Cells; Humans; Indoles; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides | 2012 |
Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Caspase 3; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; raf Kinases; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases | 2013 |
BRAF mutations in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Exons; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Sorafenib; Sulfonamides; Treatment Outcome | 2013 |
Assessment of modelling strategies for drug response prediction in cell lines and xenografts.
Topics: Animals; Biomarkers, Pharmacological; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Imidazoles; Indoles; Lapatinib; Machine Learning; Mice; Neoplasms; Organ Specificity; Paclitaxel; Piperazines; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |